Research digest

NMN Supplementation and Cellular Energy

As we age, NAD+ levels naturally decline, potentially impacting how our cells generate vital energy.

3 min readEmerging evidenceReviewed by Welcuren clinical team · 3 November 2026

This study explored how oral NMN supplementation affects blood NAD+ concentrations in healthy middle-aged adults. The results suggest a significant increase in markers of cellular health over a 60-day period.

What was studied

Maintaining cellular energy is a cornerstone of the Welcuren philosophy. This multicentre, randomised, double-blind, placebo-controlled clinical trial investigated the safety and efficacy of Nicotinamide Mononucleotide (NMN) in 80 healthy middle-aged adults. Participants were divided into groups receiving different daily amounts of NMN or a placebo for 60 days to determine how effectively the body converts these precursors into active NAD+.

What it found

The study reported that NMN supplementation was well-tolerated and significantly increased NAD+ concentrations in the blood compared to the placebo group. Those taking the highest amounts showed the most substantial increases. Furthermore, participants in the NMN groups demonstrated improved walking distance in a six-minute endurance test and reported better general health scores. This suggests that supporting our NAD+ levels may play a role in maintaining physical vitality as we grow older. If you are considering support for your cellular health, your clinician can advise whether it's suitable.

What it doesn't tell us

While the results are promising for mid-life vitality, the study was limited to a 60-day window. We do not yet have long-term data over several decades to see how these changes influence overall lifespan. Additionally, because the participants were healthy, the study does not address how those with specific pre-existing metabolic conditions might respond. Further large-scale trials are needed to standardise long-term wellness protocols.

References
  • Yi et al., 2023, GeroScience — The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial. View paper

Was this helpful?

Questions about this?

Our assistant can explain it simply, or a clinician can advise you personally.

Talk to a clinician

Educational content, not medical advice. Treatments are only prescribed after an online consultation, at a clinician's discretion.